Summary of Zoetis 2026 Conference Call Company Overview - **Company**: Zoetis (NYSE: ZTS) - **Date**: March 17, 2026 - **Speaker**: Kristin Peck, CEO Key Points Industry and Company Guidance - **2026 Guidance**: Zoetis is guiding for 3.5% organic constant currency growth after achieving 6% in 2025 [1] - **Growth Drivers**: The growth will be driven by a diverse portfolio, particularly in core therapeutic areas such as dermatology, parasiticides, and pain management [2][3] - **Livestock Growth**: Historically, livestock growth has been around 2%-4%, but Zoetis has seen mid- to high-single-digit growth over the past three years and expects to outperform the market in 2026 [3] Financial Metrics - **Price and Volume Assumptions**: The company expects 2%-3% growth from price increases and the remainder from volume for 2026 [5] - **Vet Clinic Visits**: Despite a decline in visits, spending at vet clinics grew by 6% in Q4 2025, indicating a strong human-animal bond and willingness to spend on pet care [10][11] Competitive Landscape - **Market Competition**: Increased competition in dermatology and parasiticides is expected, but Zoetis remains confident in its brand loyalty and customer satisfaction [57][58] - **New Products**: The company is focusing on long-acting pain products and expects to launch new therapies in oncology, cardiology, and renal health, which are anticipated to be high-value markets [19][20][21] Supply Chain and External Factors - **Impact of Oil Prices**: The ongoing conflict in Iran has minimal direct sales impact (less than 1% of total sales), but rising oil prices could affect shipping costs [7][9] - **Weather Impact**: Q1 2026 has seen adverse weather conditions affecting the parasiticide market, which typically performs better in Q2 and Q3 [55][56] Innovation and R&D - **AI in Drug Discovery**: Zoetis is leveraging AI for early drug discovery and molecule selection, utilizing unique datasets that include clinical trial data and genetic information [49][50][51] - **Future Products**: The company is optimistic about the potential of new products in renal health, which is projected to be a $3-$4 billion market, contingent on improved diagnostic rates [20][31] Market Trends - **Protein Demand**: The growing global population and middle-class expansion are driving protein demand, with poultry, fish, and pork being the fastest-growing sources [35][36] - **Health and Wellness Trends**: An aging population is increasing the focus on health and wellness, which is expected to support protein consumption trends [44] Strategic Changes - **Field Team Restructuring**: Zoetis has restructured its go-to-market teams to enhance reach and frequency, focusing on specialty products and chronic care [46][48] Long-Term Outlook - **2030 Vision**: Zoetis aims to continue growing its core franchises while exploring new therapeutic areas, emphasizing the importance of portfolio diversity and innovation [60][61] Additional Insights - **Customer Satisfaction**: High customer satisfaction rates (80%-90%) for key products like Apoquel and Simparica indicate strong brand loyalty [14][58] - **Veterinary Engagement**: The company is investing in professional service vets to enhance scientific conversations and support the growth of specialty products [48] This summary encapsulates the key insights and strategic directions discussed during the Zoetis 2026 conference call, highlighting the company's growth prospects, competitive landscape, and innovation strategies.

Summary of Zoetis Conference Call Company Overview - **Company**: Zoetis - **Industry**: Animal Health Key Points Companion Animal Market Insights - Overall consumer spending on pet health remains strong, with vet clinic revenues increasing by approximately 6% in Q4 2025 [2] - There is pressure on specific consumer segments, particularly millennials and Gen Z, due to financial burdens like student loans, affecting clinic visit volumes [2][3] - Corporate-owned vet clinics have seen pronounced price increases, leading to higher spending on emergency care, indicating a shift in consumer behavior towards urgent care [3] Product Performance and Growth - **Trio Product**: Generated over $1 billion in U.S. revenues, with high satisfaction levels (95%-96%) among pet owners and veterinarians [6] - Triple combination products occupy about 50% of the vet clinic patient base, with new puppies showing a higher adoption rate of these products [7][8] - Compliance rates for Trio are significantly higher in autoship channels, indicating a strong opportunity for growth in this area [10] Dermatology Segment - Key dermatology products generated $1.7 billion in revenue last year, with less than 50% of itchy dogs receiving treatment from veterinarians, indicating substantial growth potential [14][15] - Apoquel and Cytopoint are the main products in the dermatology franchise, with high satisfaction levels and ongoing conversion from Apoquel to its chewable version [20][21] - The company is focusing on increasing awareness and driving more dogs into clinics for treatment [17][18] Osteoarthritis (OA) Pain Management - Librela is showing signs of stabilization, with over 75% satisfaction among pet owners [30] - An estimated 25 million to 27 million dogs in the U.S. suffer from OA pain, with only about 1 million currently receiving Librela treatment, highlighting a significant market opportunity [31][32] Livestock Market Dynamics - Livestock growth is expected to continue at mid-single-digit rates, driven by rising animal protein consumption due to population growth and urbanization [40][41] - The livestock segment is currently growing faster than the companion animal segment, although long-term trends suggest companion animals will outpace livestock growth [42] Pipeline and Future Products - The company is excited about its pipeline, particularly in addressing renal and chronic kidney disease, with a total addressable market estimated between $3 billion and $4 billion [43][44] - Future product launches will focus on working with specialists before broader market releases to ensure effective education and data collection [34] Capital Deployment Strategy - In 2025, Zoetis returned $4 billion to investors, with a focus on investing in R&D and strategic M&A, such as acquiring part of Neogen's genomics business [45][46] - The company prioritizes business investment over cash retention, ensuring continued growth and innovation [47] Macro Economic Considerations - The company is monitoring oil price fluctuations and their potential impact on supply chain dynamics, but current levels are not expected to have significant effects [39] Additional Insights - The company emphasizes the importance of compliance and consumer education in driving product adoption and market growth across various segments [35][36] - There is a strategic focus on leveraging promotional activities in the dermatology space, which is less seasonal compared to parasiticides [23][24]

Core Viewpoint - Dividend stocks vary significantly, with some companies maintaining or increasing dividends during economic downturns, making them attractive to income-oriented investors. Johnson & Johnson and Zoetis are highlighted as strong candidates for such investors. Group 1: Johnson & Johnson - Johnson & Johnson is characterized by a consistent and resilient business model, being a leading pharmaceutical company with a diverse portfolio of approved medicines and medical devices [3] - The company anticipates annual reported sales to exceed $100 billion for the first time, despite facing challenges like patent cliffs and government drug price negotiations [4] - Johnson & Johnson boasts a strong balance sheet, with a higher credit rating than the U.S. government, and a gross margin of 67.97% [6] - The company is recognized as a Dividend King, having increased its dividends for at least 50 consecutive years, making it a reliable choice for dividend investors [8] Group 2: Zoetis - Zoetis is a leading animal health company that faced challenges last year due to safety concerns regarding its products Librela and Solensia, which treat osteoarthritis pain in pets [9] - The company has received approval for new products, Lenivia and Portela, which are longer-acting treatments and expected to capture market share [10] - Zoetis has a strong growth portfolio, including Apoquel, a breakthrough medicine for allergic itch in dogs, with significant growth potential due to a large untreated population [12] - The company has increased its dividend by 458% over the past decade, positioning it as a strong dividend stock for long-term investment [13]

Fund Performance - Impax US Sustainable Economy Fund reported a total return of 16.00% in 2025, compared to 17.37% for the Russell 1000, indicating a modest underperformance influenced by sector allocation and company-level developments [1] - The fund's performance was positively impacted by sustainability tilts and stock-specific gains, particularly in Health Care and Financials, despite overall market volatility [1] Market Conditions - Equity markets remained volatile during Q4 2025 due to concerns over elevated valuations and financing for large-scale data center investments [1] - Management expressed a cautiously optimistic outlook, supported by falling interest rates, resilient corporate earnings, and continued investment in businesses positioned for a sustainable economy transition [1] Company Focus: Zoetis Inc. - Zoetis Inc. (NYSE:ZTS) is highlighted for its attractive sustainability opportunity profile and strong governance, with a one-month return of 0.90% and a market capitalization of approximately $55.33 billion [2][3] - The company has a full pipeline of new products expected to launch, but revenue growth acceleration is anticipated to begin in 2027, facing competition and challenges with established products [3] - Disappointment was noted in Zoetis' Q3 earnings update, particularly regarding the performance of its canine arthritis pain product Librela, which faced side-effect perception issues [3]

Core Viewpoint - Zoetis Inc. reported strong fourth-quarter results for 2025, exceeding earnings expectations and demonstrating resilience across its product portfolio despite challenges in certain segments [1][5]. Financial Performance - Adjusted earnings per share for Q4 2025 were $1.48, surpassing the consensus estimate of $1.40 [1]. - Total sales reached $2.387 billion, reflecting a 3% year-over-year increase, closely aligning with the consensus of $2.36 billion [1]. - Adjusted net income was $648 million, marking a 3% increase on a reported basis and a 4% increase on an organic operational basis [1][2]. Segment Breakdown - U.S. segment revenue was $1.2 billion, down 2% on a reported basis but flat on an organic operational basis [3]. - Companion animal product sales decreased by 1%, with declines in monoclonal antibody products for osteoarthritis partially offset by growth in parasiticides and dermatology [3]. - Livestock product sales declined by 6% on a reported basis due to divestitures, but increased by 3% on an organic operational basis, driven by growth in cattle and poultry biologics [4]. Future Guidance - For fiscal 2026, Zoetis forecasts adjusted earnings of $7.00-$7.10 per share, exceeding the consensus of $6.80 [6]. - Sales projections for 2026 are between $9.83 billion and $10.03 billion, compared to the consensus of $9.91 billion [6]. Analyst Outlook - Analysts from William Blair noted that the 2026 EPS guidance is above market expectations, suggesting potential stabilization in fundamentals [7]. - Concerns were raised regarding growth in key segments such as dermatology and OA pain, which experienced a decline [7][8]. - The competitive landscape is expected to intensify, raising questions about growth and EPS improvement in 2026 [8].

Core Insights - Zoetis, Inc. (ZTS) reported fourth-quarter 2025 adjusted earnings of $1.48 per share, exceeding the Zacks Consensus Estimate of $1.40, and up from $1.40 in the same quarter last year [1] - Total revenues for the quarter increased by 3% year over year to $2.39 billion, surpassing the Zacks Consensus Estimate of $2.37 billion, compared to $2.32 billion in the prior year [1] Financial Performance - U.S. segment revenues decreased by 2% year over year to $1.24 billion, missing the Zacks Consensus Estimate of $1.27 billion [3] - Sales of companion animal products in the U.S. declined by 1% year over year to $1 billion, with growth in parasiticides and dermatology products offset by a decline in monoclonal antibody products for osteoarthritis pain [4] - Livestock product sales in the U.S. fell by 6% to $234 million, primarily due to the divestiture of the medicated feed additive product portfolio [6] - International segment revenues grew by 8% year over year to $1.12 billion, exceeding the Zacks Consensus Estimate of $1.06 billion [8] - Ex-U.S. sales of companion animal products rose by 7% to $599 million, driven by growth in key products [8] - Livestock product sales internationally increased by 9% to $522 million, supported by growth across core species [9] Full-Year Results and Guidance - For the full year 2025, Zoetis reported adjusted earnings of $6.41 per share, up from $5.92 the previous year, and total revenues of $9.47 billion, an increase of 2% year over year [10] - The company provided guidance for 2026, expecting adjusted earnings in the range of $7.00-$7.10 per share and revenues between $9.825 billion and $10.025 billion, indicating operational growth of 3-5% [11][13] Product Developments - Zoetis received EU approval for Lenivia, a long-acting monoclonal antibody therapy for canine osteoarthritis pain, with a commercial launch expected in 2026 [14] - The approval of Lenivia is anticipated to enhance Zoetis' position in the companion-animal biologics market and expand its offerings in the osteoarthritis segment [15]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [21][22] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [21][22] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [39] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [22][24] - The livestock portfolio achieved $2.8 billion in revenue, reflecting 8% organic operational growth, driven by broad-based growth across geographies and species [24][30] - Companion animal diagnostics delivered 13% operational revenue growth, supported by the launch of new products like Vetscan OptiCell and Imagyst [16][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [7][21] - International companion animal revenue grew 7% operationally, driven by the Simparica and key dermatology franchises [28] - The international livestock portfolio grew 10% on an organic operational basis, with strong performance in cattle and poultry markets [30] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth opportunities [8][19] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and reinforcing scientific leadership [9][20] - The company aims to leverage its diverse portfolio and robust pipeline, with 12 potential blockbusters in development [19][20] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are economic pressures affecting pet owners, demand for animal health services remains strong [10][71] - The company expects gradual improvement in the macro environment as it moves through 2026, with guidance for 2026 set at 3%-5% organic operational revenue growth [18][42] - Management emphasized the importance of innovation and strategic execution in navigating competitive pressures [19][20] Other Important Information - The company completed a convertible bond offering to support a $1.75 billion common stock buyback while maintaining a strong balance sheet [42] - A multi-year initiative to transition the ERP system is underway to enhance operational efficiency and reporting capabilities [38] Q&A Session Summary Question: Competition and Pricing Dynamics for 2026 - Management acknowledged the competitive landscape and the impact of aggressive promotions on growth, particularly in the dermatology space [50][51] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - The guidance incorporates current market conditions and the company's strong portfolio, with expectations for continued demand despite competitive pressures [55][56] Question: Dynamics of Simparica Trio Growth - Management highlighted the significant room for expansion in the triple combination space, with expectations for continued growth in 2026 [62] Question: Revenue Recognition and Accounting Changes - Management clarified that operational changes have resulted in some revenue deferrals, which will be factored into future guidance [61][63]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [21][22] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [21][22] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [39] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally in 2025, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [22][24] - The livestock portfolio achieved $2.8 billion in revenue, reflecting 8% organic operational growth, driven by broad-based growth across geographies and species [24][30] - Companion animal diagnostics delivered 13% operational revenue growth for the year, supported by the launch of new products [16][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [7][21] - The international companion animal business grew 7% operationally, driven by the Simparica and key dermatology franchises [28][30] - Livestock performance was particularly strong in the Brazilian cattle market, with broad-based growth across all core species [30][37] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth opportunities [8][19] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and reinforcing scientific leadership [9][10] - The company aims to leverage its diverse portfolio and innovative capabilities to drive long-term growth and value creation [20][46] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are economic pressures affecting pet owners, demand for animal health services remains strong [10][71] - The company expects gradual improvement in the macro environment as it moves through 2026, with guidance for 2026 set at 3%-5% organic operational revenue growth [18][42] - Management remains confident in the long-term fundamentals of the livestock market, driven by increasing protein consumption and favorable producer economics [18][30] Other Important Information - The company completed a convertible bond offering to support a $1.75 billion common stock buyback while maintaining a strong balance sheet [42] - A multi-year initiative to transition the ERP system is underway, aimed at enhancing operational efficiency and insight [38] Q&A Session Summary Question: Competition and Pricing Dynamics for 2026 - Management acknowledged the competitive landscape and the impact of new product launches on growth, particularly in the dermatology space [50][51] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - Management indicated that the guidance incorporates current market conditions and the strength of the company's portfolio, despite competitive pressures [55][56] - The demand for animal health remains resilient, with consumers prioritizing spending on their pets [56][71] Question: Dynamics of Simparica Franchise Growth - The Simparica franchise continues to lead in the U.S. market, with significant room for expansion despite recent lower growth rates [62] - Management emphasized the importance of maintaining a strong market position and adapting to competitive pressures [62] Question: Revenue Recognition and Accounting Dynamics - Management clarified that operational changes have led to some revenue recognition shifts, which are factored into the guidance for 2026 [61][63] - The one-month lag in revenue recognition will be addressed with the implementation of fiscal year alignment in early 2026 [61][63]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [20][21] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [20][21] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [40] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally in 2025, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [21][22] - The livestock portfolio delivered 8% organic operational revenue growth for the year, with $2.8 billion in revenue [24][30] - Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year [14][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [5][20] - International companion animal grew 7% operationally, driven by the Simparica and key dermatology franchises [27] - International livestock grew 10% on an organic operational basis, with strong performance in the Brazilian cattle market [30] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth [6][18] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and increasing reach with veterinarians [8][19] - The company aims to leverage its diverse portfolio and robust pipeline, with 12 potential blockbusters in development [18][19] Management Comments on Operating Environment and Future Outlook - Management noted that the operating environment is dynamic, with macroeconomic pressures affecting consumer behavior, particularly among Gen Z and millennial pet owners [6][9] - Despite near-term headwinds, management remains confident in the long-term fundamentals of the animal health market, expecting gradual improvement in 2026 [9][17] - Guidance for 2026 includes organic operational revenue growth of 3%-5% and adjusted net income growth of 3%-6% [42][43] Other Important Information - The company is transitioning its ERP system to enhance operational efficiency and align fiscal years globally [39][40] - A convertible bond offering supported a $1.75 billion common stock buyback, returning over $3.2 billion to shareholders through buybacks and dividends [42] Q&A Session Summary Question: Competition and Pricing Strategy for 2026 - Management acknowledged the competitive landscape and the impact of new product launches on growth, particularly in the dermatology space [48][50] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - Management indicated that the guidance incorporates current market conditions and the strength of their portfolio, despite competitive pressures [56][57] Question: Dynamics of Simparica Trio Growth - Management highlighted that Simparica Trio remains a leading product with significant room for expansion, despite recent lower growth [61][63]

Core Insights - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its fourth-quarter 2025 earnings report, scheduled for February 12, 2026, with revenue estimates at $2.37 billion and earnings per share (EPS) at $1.40 [1][5] Group 1: Revenue Expectations - The Zacks Consensus Estimate for U.S. segment revenues is projected at $1.27 billion, likely reflecting a decrease from the previous year due to lower sales of companion animal products [3][5] - International segment revenues are expected to rise to $1.06 billion, driven by increased sales of companion animal products [4][5] Group 2: Product Performance - Sales of companion animal products, particularly from the parasiticides portfolio (including Simparica and Revolution) and key dermatology products (Apoquel and Cytopoint), are expected to contribute positively to revenues in both U.S. and International segments [7] - However, sales of monoclonal antibody products for osteoarthritis pain (Librela for dogs and Solensia for cats) are anticipated to decline in the U.S. due to concerns over side effects, potentially offsetting gains from other product categories [8] Group 3: Regulatory Developments - The FDA approved a new indication for Zoetis' Simparica Trio in 2025, which is expected to enhance sales by preventing flea tapeworm infections in dogs [10] Group 4: Historical Performance - Zoetis has a strong earnings surprise history, having surpassed estimates in each of the last four quarters with an average surprise of 5.37% [13]